UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2023

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

	Nevada	001-39082	45-5401931
	(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	2222 Ponce de Leon Blvd, Floor 3 Coral Gables, FL		33134
	(Address of principal executive offices		(Zip Code)
	Registra	nt's telephone number, including area code: (786) 629	1376
	(For	mer name or former address, if changed since last rep	ort)
	ck the appropriate box below if the Form 8-K filing is interal Instruction A.2. below):	ended to simultaneously satisfy the filing obligation	of the registrant under any of the following provisions (see
	Written communications pursuant to Rule 425 under the S	Securities Act (17 CFR 230.425)	
	Soliciting material pursuant to Rule 14a-12 under the Exc	hange Act (17 CFR 240.14a-12)	
	Pre-commencement communications pursuant to Rule 14	d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)	
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
Securities registered pursuant to Section 12(b) of the Act:			
	Title of each class Common stock, \$0.001 par value per share	Trading Symbol RLMD	Name of each exchange on which registered The NASDAQ Global Select Market
	Securities Exchange Act of 1934 (§240.12b-2 of this chapter		ies Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
			Emerging growth company \square
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial			
accounting standards provided pursuant to Section 13(a) of the Exchange Act.			
Iton	n 7.01 Regulation FD Disclosure.		
		at hold and dampaits an equivities at Ciliaan Vallay Da	w.l.
Relmada Therapeutics, Inc., informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank.			
othe			18 of the Securities Exchange Act of 1934, as amended, or eference into any registration statement or other document
		1	
		SIGNATURES	

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly

authorized.

Dated: March 13, 2023

By: /s/ Sergio Traversa
Name: Sergio Traversa
Title: Chief Executive Officer

RELMADA THERAPEUTICS, INC.